Live Sessions
Can’t make it to a live session? Register anyway and we will send you the recording.
Calculating Risk and Return in Oncology Development Webinar
9AM — 10 am (ET) / 3 pm — 4 pm (CET)
Webinar recording
Calculating Risk and Return in Oncology Development Webinar
9AM — 10 am (ET) / 3 pm — 4 pm (CET)
In this session, we investigate macro trends and forecasts in oncology using proprietary EvaluatePharma and Evaluate Omnium metrics, and offer perspectives from our work on the best frameworks and methodologies to quantify risk and return in highly dynamic oncology markets.
This live session will be animated by:
- Dr. Paul Verdin, Head of Custom Solutions at Evaluate
- Henry Barling, Senior Oncology Analyst at Evaluate
Webinar recording
Events Preview & Platform Demo Webinar
10AM — 11 am (ET) / 4 pm — 5 pm (CET)
Get an insider’s preview of Inova & BIO’s upcoming Virtual Partnering events in March: Oncology Virtual Partnering 2-5 March and Immunology Virtual Partnering 9-12 March
Our team from Inova, BIO and Evaluate will animate a live session on:
- Who’s attending: company and asset profiles
- A walk-through of Inova’s best-in-class One-on-One Partnering™ platform
- The ins & outs of Virtual Partnering and how to make the most of the event
- Webinar sessions during the events
- Q&A
Trends in New Oncology Treatments Webinar
2PM — 2:45 pm (CET) / 8 am — 8:45 am (ET)
Webinar recording
Trends in New Oncology Treatments Webinar
2PM — 2:45 pm (CET) / 8 am — 8:45 am (ET)
Record number of new oncology treatments have been approved in recent years, bringing new treatment options to patients. Although recent progress has deepened our understanding of the disease and has also brought on unprecedented new possibilities for personalized medicine, there are still many cancer types for which there are no, or minimally, effective therapy. Leaders in the field will discuss the latest breakthroughs in oncology research, the impact of COVID-19 on oncology drug development and insights on future trends in oncology treatment and the financial landscape for these promising new therapies.
The panel will focus on:
- Latest development in oncology R&D
- Including Real World Evidence and its uses to glean information about patients with molecular subsets of cancers
- Advancements in Cell Therapy
- What was hot at ESMO
- Perspectives on investment landscape in oncology
- AI/ML
